Distalmotion receives FDA clearance for additional gynecology indications
The DEXTER Robotic Surgery System is cleared for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection.
See the latest news and media coverage for Distalmotion. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of robotic surgery systems
distalmotion.comLast updated
In short: Distalmotion expanded the US commercial footprint of its DEXTER robotic system following FDA clearances and a $150 million Series G funding round.
The DEXTER Robotic Surgery System is cleared for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection.
It follows SPARO trial completion. Clearance adds fourth US indication, second in gynecology, aiding outpatient procedures. CEO highlights outpatient robotics evolution.
The study documents the use of DEXTER® in robot-assisted partial nephrectomies with solid results in safety and performance.
The case occurs at Klinikum Landkreis Erding days after installation, integrating into routine workflows. Early application builds sustainable robotic programs.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around...
Swiss medical device company Distalmotion has secured the US Food and Drug Administration (FDA) 510(k) clearance for its DEXTER robotic surgery system, covering sacrocolpopexy, sa...
The company is seeking clearance in additional gynecological indications to support outpatient use of its surgical robot.
Distalmotion’s Dexter surgical robotics system challenges the clinical and economic barriers that limit ambulatory surgical centers’ access to innovation.
Track Distalmotion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Distalmotion and other trending companies.